Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
InflaRx ( (IFRX) ) just unveiled an update.
InflaRx N.V. announced its annual general meeting of shareholders scheduled for April 24, 2025, in Amsterdam. The agenda includes discussions on the company’s 2024 financial year report, adoption of annual accounts, and several voting items such as the appointment of KPMG as the auditor for 2025 and the extension of authorizations for the board regarding shares and pre-emption rights. These proceedings are crucial for the company’s governance and strategic planning, impacting shareholder relations and future business operations.
More about InflaRx
InflaRx N.V. is a biotechnology company based in Jena, Germany, focusing on developing anti-inflammatory therapeutics. The company is primarily engaged in creating treatments for inflammatory diseases, utilizing its expertise in complement system inhibition.
YTD Price Performance: -54.00%
Average Trading Volume: 390,789
Technical Sentiment Signal: Strong Buy
Current Market Cap: $70.49M
For an in-depth examination of IFRX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue